Cell Therapy Blog welcomes 2013
By Dr. Matthew Watson
- a post summarizing some of the things we think are watch-worthy in the cell therapy industry in 2013,
- our recap of the money cell therapy and cell-based regenerative medicine companies raised in 2012, and
- us to formalize our position statement on non-compliant cell therapies as discussed in following previous blog posts:
Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html
Presents at cell biology gathering – The Sunday Dispatch
By Dr. Matthew Watson
Presents at cell biology gathering The Sunday Dispatch Yurko hopes to earn a Ph.D. in biochemistry and molecular genetics and plans a career in biomedical research specializing in autoimmune and multi-drug resistant diseases. “I have found a way I can help people. It took me a while, but I now know it is ... |
Uncategorized
Comments Off on Presents at cell biology gathering – The Sunday Dispatch |
January 6th, 2013
Stem Cell Therapy for Autism, Mumbai, India – Video
By NEVAGiles23
Stem Cell Therapy for Autism, Mumbai, India
By: Rajeev Ranjan
View original post here:
Stem Cell Therapy for Autism, Mumbai, India - Video
Uncategorized
Comments Off on Stem Cell Therapy for Autism, Mumbai, India – Video |
January 6th, 2013
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video
By LizaAVILA
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost
stemcellmalaysia.com Stem cell therapy is not a cheap medical treatment. In fact, it is very expensive treatment to the majority of people. The high price of stem cell therapy becomes not only a deterrent to the majority but also creates room for non-medical sector to fill the void of demands for disease treatment. This video addresses the issues surrounding the cost of stem cell therapy, particularly in Malaysia. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.com
By: stemcells2012
Read more from the original source:
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost - Video
Uncategorized
Comments Off on Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost – Video |
January 4th, 2013
Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
By NEVAGiles23
Centagen has developed a breakthrough stem cell therapy that rejuvenates a patient's own adult stem cells. The Company has found a way to expand a patients own stem cells in the lab millions of times while rejuvenating the cells. For example, a patients blood pleuropotent stem cells could be rejuvenated and expanded in the lab and then re-injected to repair and rejuvenate organs and tissues damaged by aging or disease. Centagen has announced a funding campaign at http://www.indiegogo.com/centagen for additonal research and development.
Boulder, Colorado (PRWEB) December 31, 2012
Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding ones own stem cells could help with Alzheimers disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.
The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patients adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.
Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make 100 years old the new 50.
Forward-Looking Statements for Centagen, Inc.
This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.
Bryant Villeponteau, Ph.D. Centagen (877) 757-1923 Email Information
Uncategorized
Comments Off on Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc. |
December 31st, 2012
Stem Cell Therapy at IMC Dr.Omar Gonzalez – Video
By LizaAVILA
Stem Cell Therapy at IMC Dr.Omar Gonzalez
New Project 70
By: OmarGonzalezMD
Excerpt from:
Stem Cell Therapy at IMC Dr.Omar Gonzalez - Video
Uncategorized
Comments Off on Stem Cell Therapy at IMC Dr.Omar Gonzalez – Video |
December 30th, 2012
Thursday Sector Leaders: Textiles, Biotechnology Stocks – Forbes
By Dr. Matthew Watson
Thursday Sector Leaders: Textiles, Biotechnology Stocks Forbes Also showing relative strength are biotechnology shares, up on the day by about 0.9% as a group, led by Synergy Pharmaceuticals DE (SGYP), trading up by about 7% and Astex Pharmaceuticals (ASTX), trading higher by about 6.9% on Thursday. comments ... |
Uncategorized
Comments Off on Thursday Sector Leaders: Textiles, Biotechnology Stocks – Forbes |
December 30th, 2012
PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC – Frontier Post
By Dr. Matthew Watson
PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC Frontier Post Dr Akmal Rahim did his PhD in Botany while his wife Dr Farkhunda Jameel did her PhD in Molecular Biology and Molecular Genetics. Dr Saadat Ali and his wife Dr Ishrat Aziz did their PhDs in biological sciences. Dr Ans Nazar did his PhD in Islamic Studies. Interesting facts at PU convocationThe News International |
Uncategorized
Comments Off on PU 121st Convocation Rulers cut educational budget from 2 to 1.5%: VC – Frontier Post |
December 30th, 2012
Lessons from Prop 37 and the future of genetic engineering in agriculture – UC Berkeley (blog)
By Dr. Matthew Watson
Lessons from Prop 37 and the future of genetic engineering in agriculture UC Berkeley (blog) I was a strong opponent of Proposition of 37 and I am quite satisfied that it did not pass; but its failure serves more than vindication. It has interesting implications for the attitude of California on environmental issues, the future of GMOs, and ... |
Uncategorized
Comments Off on Lessons from Prop 37 and the future of genetic engineering in agriculture – UC Berkeley (blog) |
December 23rd, 2012
Delaware Biotechnology Institute hosts reception for IGERT Scholars – University of Delaware
By Dr. Matthew Watson
 University of Delaware | Delaware Biotechnology Institute hosts reception for IGERT Scholars University of Delaware 18, 2012--The Delaware Biotechnology Institute (DBI) hosted a reception Tuesday, Dec. 11, for the first cohort of five IGERT Scholars participating in the new National Science Foundation-supported Integrative Graduate Education and Research Traineeship ... |
Uncategorized
Comments Off on Delaware Biotechnology Institute hosts reception for IGERT Scholars – University of Delaware |
December 23rd, 2012
Burrill Starts Prana Biotechnology (PRAN) at Market Outperform – StreetInsider.com (subscription)
By Dr. Matthew Watson
Burrill Starts Prana Biotechnology (PRAN) at Market Outperform StreetInsider.com (subscription) The firm comments, "We are initiating coverage on Prana Biotechnology, that is developing a platform technology to address the potential causes of neurodegenerative disorders. Prana is undervalued relative to its peer group, in our view." "We believe ... |
Uncategorized
Comments Off on Burrill Starts Prana Biotechnology (PRAN) at Market Outperform – StreetInsider.com (subscription) |
December 23rd, 2012
The Accuracy of Adipose Stem Cell Doses
By Dr. Matthew Watson
In August we published a blog post, "Are some cell counts too good to be true? Why some companies' product data may mislead", pointing people to a white paper released by INCELL Corporation. That white paper appears now to have been pulled from their website (we are working to get a copy to make available again) but now they have published a paper providing more detailed data on aspects of their comparative cell count study.
The paper is introduced by the following abstract:
"Cell therapy products derived from adipose tissue have some unique processing issues with regard to obtaining accurate cell counts. This is because processing methods may not only show us the nucleated stromal vascular fraction (SVF) cells but also the micellular and microvesicle particles. This is true for both veterinary and human clinical products, and poses special concerns for in-clinic processing where the cell therapy dose is correlated with cell numbers and other QC data is not especially useful.
In this study, multiple cell counting methods were compared for SVF cell reparation that were derived from canine adipose tissue using commercially-available rocessing kits. The data clearly showed that many non-nucleated particles appear cell-like by size and shape, and can lead to counting errors with automated counters. In addition, certain reagents important to processing can have properties wherein the reagents alone (e.g., lecithin) may be counted as cells. The most accurate cell numbers were from hemocytometer-counting of cells stained with 4ยด,6-diamidino-2-phenylindole (DAPI) which shows the nuclei in concert with a viability stain such as trypan blue. The data clearly showed that care must be taken when counting cells used as a therapeutic dose."
This is an important issue particularly as it pertains to autologous cell-based treatments produced by point-of-care devices and/or kits. I encourage you to read the paper.
Morrison DG, Hunt DA, Garza I, Johnson RA, Moyer MP*. Counting and Processing Methods Impact Accuracy of Adipose Stem Cell Doses. BioProcess J, 2012; 11(4): 4-17.
* Dr. Moyer is CEO and Chief Science Officer for INCELL Corporation, 12734 Cimarron Path, San Antonio, Texas 78249 USA. http://www.incell.com
Mucopolysacccharidoses: from understanding to treatment, a century of discoveries
By Dr. Matthew Watson
After the first description of a patient recognized as a MPS case was made in 1917, several similar cases were described and identified. Observations reported in the middle of the twentieth century concerning the presence of acid mucopolysaccharides (later called glycosaminoglycans, or GAGs) in tissues and especially in urine of patients were instrumental in providing an identity for these diseases, which became referred as "mucopolysaccharidoses" (MPS). In the late 1960's it was demonstrated that MPS were caused by defects in the breakdown of GAGs, and the specific enzyme deficiencies for the 11 types and subtypes of MPS were identified thereafter. Genes involved in the MPS were subsequently identified, and a large number of disease-causing mutations were identified in each one. Although ...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Uncategorized
Comments Off on Mucopolysacccharidoses: from understanding to treatment, a century of discoveries |
December 23rd, 2012
San Diego Newspaper Calls for Major Changes at California Stem Cell Agency
By Dr. Matthew Watson
The San Diego U-T today ran an
editorial that was headlined “Stem cell research institute must fix itself.”
to findings by the Institute of Medicine that the $3 billion
California stem cell should make sweeping changes to deal with issues
ranging from conflicts of interest to management structure.
a unanimous reaction so far from California newspapers.
“We hope we
are wrong in thinking that, given the number of times the same
criticisms of CIRM have come up over the past seven years, the agency
doesn’t really take them seriously.
“If that is
the agency’s attitude, it could well be a fatal error. CIRM has
enough money remaining from the original $3 billion to continue
awarding research grants for another four years. But it will either
have to go back to California voters in 2014 or 2016 for another bond
issue to continue its operations or find a different source of
funding.
“Whichever
CIRM decides, whoever is asked to foot the bill, either taxpayers or
the private sector will demand transparency and accountability. We
hope CIRM can demonstrate it.”
Source:Stem Cell Therapy
Comments Off on San Diego Newspaper Calls for Major Changes at California Stem Cell Agency |
December 23rd, 2012
Boxing in the California Stem Cell Board
By Dr. Matthew Watson
Robert Klein is much admired for his
prodigious efforts on behalf of stem cell research, including his
service as the first chairman of the $3 billion California stem cell
agency.
directing the ballot campaign that resulted in passage of Proposition
71 in 2004 and creation of of the agency. One of Klein's less
publicly recognized skills was putting the governing board of the
agency in a box from time to time.
be headed for another box – this time in connection with their
position on the Institute of Medicine's sweeping recommendations for major changes at the stem cell agency.
similar situation in 2009 involving Klein and the Little Hoover
Commission, the state's good government agency.
the commission, which was requested by state lawmakers who had butted
heads with Klein. He knew that the commission would come up with
recommendations that he would find odious.
released in its final form, Klein had the board's outside counsel,
James Harrison, prepare a legal memo on a draft version of the study.
Harrison's memo said many of the most far-reaching recommendations of
the commission would require a vote of the people – a more costly
and unlikely proposition than a vote of the legislature.
2009. The commission report was released June 26, 2009. On June 30, 2009, Klein warned directors in an email that support of some of the
proposals would violate their oath of office. The first time a
subcommittee of directors had to a chance to react publicly came on
July 16, 2009. The full board did not have the Hoover report on its
agenda until Aug. 6, 2009. By that time, they were thoroughly boxed
in.
they disagreed with Klein. To do anything other than go along with
him would mean rejection of a 10-page legal opinion from Harrison,
which could be interpreted as no-confidence vote on Harrison and
possibly Klein. Board members were not interested in losing
Harrison, who has been valuable asset to the board since day one.
Overthrowing Klein was even less likely in 2009.
2009 memo in the wake of the Institute of Medicine recommendations,
which echo some of the major Hoover proposals. The board has also
scheduled a workshop for Jan. 23 that will discuss the IOM proposals.
that is as explicit as the 2009 document, CIRM directors will have
few choices. The best procedure may well be for Harrison
to continue his work on the memo until after the Jan. 23 meeting.
Directors could then decide on initial steps in connection with the
IOM recommendations and ask Harrison how they can proceed legally, although the task is really more of a political challenge than a legal
one.
Source:Exploring the Straw Man Argument Against IOM Reforms at California Stem Cell Agency
By Dr. Matthew Watson
Constitutional objections to some of
the Institute of Medicine's sweeping recommendations for changes at
the $3 billion California stem cell agency amount to little more than
a straw man, at least based on a legal memo produced earlier by the
agency.
agency were initially advanced in 2009 when the stem cell agency was
fighting an unwelcome analysis of its activities by the state's good
government agency, the Little Hoover Commission. The objections were
voiced again at a meeting earlier this month by some governing board
members, particularly Sherry Lansing, who is also chairwoman of the
University of California regents. Her comments came within minutes of
the start of the Institute of Medicine's (IOM) presentation to the
board.
because of requirements in Proposition 71, the ballot initiative that
created the stem cell agency, which is formally known as the
California Institute for Regenerative Medicine(CIRM). While Lansing
did not elaborate, some of the initiative is written into the state
constitution, which can only be amended by a vote of the people.
However, Proposition 71 can also be amended by a 70 percent vote of
each house of the Legislature and the signature of the governor,
which is no small task to achieve.
below) dealt with the recommendations of the Little Hoover
Commission, some of which were cited and echoed by the IOM. The legal
memo contended that the legislature was barred from making major
changes in the structure of the stem cell agency governing board
because the changes supposedly would not “enhance the ability of
the (agency) to further the purposes of the grant and loan programs.”
The argument was that only the people could make “non-enhancing”
changes. The vague “enhancement” requirement was written into
Proposition 71 by its authors, one of whom is James Harrison, the
outside counsel to the board, who was also the lead author on the
2009 memo. Harrison is revisiting the supposed constitutional issues in the wake of the IOM study.
so vague as to permit wide interpretations. Certainly, removing
public suspicion about conflicts of interest would seem to help move
the agency forward. Straightening out the muddled management
structure of the agency, with its overlapping responsibilities for
the chairman and president, would certainly seem to enhance the
functioning of the agency. Assuring that the governing board has the
full ability to exercise strong oversight over the conduct of the
agency would certainly seem to be an enhancement and long overdue.
prestigious body of its sort says. The Institute of Medicine studied
the agency for 17 months under a $700,000 contract with CIRM. The
IOM's charge was to evaluate the performance of the agency and make
recommendations for improvements. The IOM recommendations echoed
findings not only of the Little Hoover Commission, but some in two
earlier studies also funded by the agency.
IOM findings and turn away would be to indicate that their earlier
admiration and respect for the IOM was something of a sham or, more
likely, now inconvenient.
does or does not enhance the agency's mission, the 29-member board
could simply adopt a resolution declaring that all the IOM
recommendations would enhance the CIRM mission.
earlier recommendations for changes was Robert Klein, the first
chairman of the agency board. Klein, an attorney and real estate investment
banker, also directed the writing of Proposition 71 and wrote
portions of it himself. He would often make numerical code citations
to the initiative during agency board meetings.
leaving in 2011 at the end of his term. He was replaced by Jonathan
Thomas, a Los Angeles bond financier, who has ushered in a new and
different era at the stem cell agency. Some might say a more
reasonable era. He says he and governing board
take the IOM study seriously.
Jan. 23 at a public workshop at the Claremont Hotel in Berkeley, Ca.,
the day before the regular board meeting. .
far written about them. The newspapers believe that the proposals
would indeed enhance the agency's mission and are, in fact, necessary
if the agency is to survive beyond 2017, when the money for new
grants runs out.
currently mulling the future of their efforts. If they are to be
successful in raising additional hundreds of millions of dollars –
be they private or public – the directors must confront the
findings of the IOM in a forthright manner. And they must move to
dispel the cloud that now hangs over the stem cell agency.
2009 legal memo can be found below. Also below is another related
legal memo from Americans for Cures, a stem cell lobbying group
sponsored by Robert Klein at the same time he was chairman of the
stem cell agency. Despite the language on the Americans for Cures
memo, it is a public record. It became a public document when Klein
submitted it to the Little Hoover Commission.)
Source:Stem Cell Therapy
Comments Off on Exploring the Straw Man Argument Against IOM Reforms at California Stem Cell Agency |
December 23rd, 2012
Balloting Begins on Stem Cell Person of the Year
By Dr. Matthew Watson
begun, with about 1,000 ballots cast so far. But only one vote truly
counts. That belongs to Paul Knoepfler, who is running the The Stem
Cell Person of the Year contest and will pony up $1,000 of his
hard-earned cash to honor the winner.
to advocates. Voting began instantly and will continue until Dec. 31
at 11:59 p.m. Votes will count for something, but Knoepfler makes it clear that they are only advisory. He makes the decision.
contest. The UC Davis stem cell researcher, patient advocate and
blogger wants to recognize someone who made a difference and took
some risks in doing so.
candidates on Knoepfler's blog, but we wanted to note that they have
a father and son competing against each other – Don Reed and his
son, Roman. (Could be tense around the holiday tables in the
Reeds' households.) Also on the list is Jeanne Loring of Scripps,
whose nominator said engages the wider community with great
effectiveness. I once heard Loring say that every stem cell
researcher should have a spiel that could be delivered in five
minutes in a taxi and that would not only explain stem cell research,
but persuade the cab driver of its virtues.
recommend them. Knoepfler will be chewing his fingernails before this
is all over.
Source:Stem Cell Therapy
Comments Off on Balloting Begins on Stem Cell Person of the Year |
December 23rd, 2012
California Editorial Unamity: Stem Cell Agency Needs Revamp
By Dr. Matthew Watson
With the addition of another editorial
this week, reaction among California newspapers so far has been
unanimous that the $3 billion California stem cell agency should heed
the sweeping recommendations of the prestigious Institute of
Medicine.
“Good intentions do not justify poor
practice.”
the agency “needs to revamp its governance structure to avoid
potential conflicts of interest and boost public confidence in the
agency.”
90 percent of its funding go to institutions with ties to directors, but also supported other recommendations, including elimination of the dual executive arrangement at the research effort.
“An agency spending Californians’
money has no business being cavalier about good government practice
and ethical safeguards — no matter how promising the potential
therapies might be. The stem-cell institute is not a private fiefdom,
but a taxpayer-supported undertaking. Yet many on the stem-cell
institute’s board objected this month to the report’s
recommendations.
“The agency also said that Prop. 71’s
provisions mean that enacting many of the proposed fixes would
require either a supermajority vote of the Legislature or another
ballot measure. That prospect should warn Californians about the
dangers of voting for complex, costly, politically driven initiatives
that have little to do with fundamental state duties.
“Still, the stem-cell agency cannot
just sit on these recommendations without damaging its credibility.
The search for medical breakthroughs does not justify ignoring vital
safeguards for spending taxpayer dollars.”
For a look at other editorials, see here and here.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/70xi8-waM7k/california-editorial-unamity-stem-cell.html
Stem Cell Therapy
Comments Off on California Editorial Unamity: Stem Cell Agency Needs Revamp |
December 23rd, 2012
Southern California Newspaper Tackles Stem Cell Agency and UC Irvine Grants
By Dr. Matthew Watson
The Orange County Register today zeroed
in on the $3 billion California stem cell agency and its relationship
to the local University of California campus in the wake of sweeping
recommendations for changes at the eight-year-old agency.
headlined “Ties to stem cell board lucrative.”
the firm's partnership with Frank LaFerla of UC Irvine, which is located in Orange County.
reviewers at the stem cell agency but the governing board of the
agency (CIRM) approved it on a 7-5 vote in September following
lobbying on behalf of the company by the board's former chairman,
Robert Klein, and others.
Medicine (IOM) and some of its findings, particularly those dealing
with conflicts of interest, echoed criticisms that have been raised for years.
“Repeated independent reviews of the
agency, including one by the (IOM) released this month, have found
that its board is rife with conflicts of interest. In fact, of the
$1.7 billion that the agency has awarded so far, about 90 percent has
gone to research institutions with ties to people sitting on the
board, according to an analysis by David Jensen at the California
Stem Cell Report, which closely follows the agency's operations.
cure, Petersen said,
“What's clear already is that the
money has transformed stem cell research in California and poured
hundreds of millions of dollars into the state's universities,
including UC Irvine.”
is dominated by members from the UC system, including two professors
at UC Irvine.
“Before Proposition 71 (the measure
that created the agency) passed, UC Irvine had less than ten stem
cell scientists, who received about $1.5 million in funding each
year. Now, after receiving $100 million in grants from the state
agency, the university has sixty scientists working to advance stem
cell research and teaching. It touts itself as one of the top stem
cell research centers in the world. In 2010, it opened an $80 million
four-story stem cell research center with the agency picking up $27
million of the cost.
“As UC Irvine has won increasing
amounts of taxpayer money, its two professors who sit on the agency's
board have risen in status on campus.
Susan Bryant
UC Irvine photo
“Professor Susan Bryant, an expert in
regenerative medicine, was dean of the School of Biological Sciences
when she was named to the agency's board in 2004. She was then
promoted to vice-chancellor of research. In July, she was named the
university's interim executive vice-chancellor and provost, its
second most powerful administrator.
“When Professor Oswald Steward, a
stem cell scientist, joined the agency's board in 2004, he was
director of UCI's Reeve-Irvine Research Center for Spinal Injury.
Since then, the scientists working in his center have received
millions of dollars in grants from the agency. In May, the university
rewarded Steward with an additional title: senior associate dean of
research for the School of Medicine.”
“The two professors are prohibited
from receiving any agency funds for their own scientific work. But so
much money has been funneled into the stem cell field in California
that it can be difficult to show their continued scientific efforts
are not somehow benefiting. For example, Bryant co-authored a
scientific article in 2009 with nine other scientists about the
genetics of salamanders, which can regenerate limbs. In the report,
the group recognized the state agency for partially funding their
work. Bryant said that the money was received by another scientist in
the group who was not employed by UC Irvine. She said the state
agency has never given a grant for research involving salamanders. 'I
have never-ever benefited from CIRM funding,' Bryant said using the
agency's acronym.
Os Steward
UC Irvine photo
“Steward said he stopped his stem
cell research when he joined the board in 2004. His board position,
he said, 'has prevented me from taking on lines of research I
otherwise would do.'
“Tom Vasich, a campus spokesperson,
said Bryant and Stewart's positions on the agency's board played no
part in their promotions and success at the school.”
Steward and Bryant are not allowed to vote on grants to UC Irvine.
University of California has 16 members on the 29-member board. One
of those is the chairwoman of the UC Regents, Sherry Lansing.
Petersen also noted that three of the UC officials, including
Steward, hold seats on the board as patient advocates.
Register's staff, joining it in November as an investigative
reporter. She worked as a business reporter for the New York Times and authored "Our Daily Meds," a book about the pharmaceutical industry. She shared in the top award in newspaper financial journalism when she was at the San Jose Mercury News.
Source:Stem Cell Therapy
Comments Off on Southern California Newspaper Tackles Stem Cell Agency and UC Irvine Grants |
December 23rd, 2012
Defining the terms – Quad City Times
By Dr. Matthew Watson
Defining the terms Quad City Times According to About.com's Biotech Guide, a GMO “can be any plant, animal or microorganism which has been genetically altered using molecular genetics techniques such as gene cloning and protein engineering.” On the other hand, according to About.com ... |
Uncategorized
Comments Off on Defining the terms – Quad City Times |
December 23rd, 2012